Metastatic renal cell carcinoma: Recent advances and current therapeutic options

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 235-245

  Schrader, Andres Jan ^a   Hofmann, Rainer ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Mammalian target of rapamycin inhibitors; Metastasis; Monoclonal antibodies; Renal cell cancer; Systemic treatment; Tyrosin kinase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMYLASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; BEVACIZUMAB; CEDIRANIB; DOXORUBICIN; EVEROLIMUS; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELOXICAM; MONOCLONAL ANTIBODY; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL LIPASE; VATALANIB; VOLOCIXIMAB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EVENING DOSAGE; FATIGUE; FEVER; FLU LIKE SYNDROME; HAIR COLOR; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERAMYLASEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPASEMIA; HYPERLIPIDEMIA; HYPERMETABOLISM; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; ISCHEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONCLEAR CELL RENAL CELL CARCINOMA; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BLEEDING; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; KIDNEY TUMOR; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS;

EID: 45549103672     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f444de     Document Type: Review

References (58)

1. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001; 88:818-824.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
3. Surveillance Epidemiology and End Results. National Cancer Institute; 2007. www.seer.cancer.gov.
4. Whelan P. The medical treatment of metastatic renal cell carcinoma. EAU Update Ser 2003; 1:237-246.
5. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.
6. Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 2006; 132:137-149.
7. Schrader AJ, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU Int 2006; 97: 461-465.
8. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23:1028-1043.
9. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28:488-494.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
12. Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007; 25 (abstract 5024).
13. Rosenberg JE, Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Bukowski RM, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol 2007; 25 (abstract 5095).
14. Srinivas S, Roigas J, Gillessen S, Harmenberg U, de Mulder PH, Fountzilas G, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results. J Clin Oncol 2007; 25 (abstract 5040).
15. Gore ME, Porta C, Oudard S, Bjarnason G, Castellano D, Szczylik C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25 (abstract 5010).
16. George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 2007; 25 (abstract 5035).
17. Unnithan JS, Choueiri T, Garcia J, Dreicer R, Laura W, Bukowski R, et al. Safety of VEGF-targeted tyrosine kinase inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Oncol 2007; 25 (abstract 5047).
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
19. Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007; 25 (abstract 5023).
20. Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007; 25 (abstract 5011).
21. Ryan CW, Bukowski RM, Figlin RA, Knox JJ, Hutson TE, Dutcher JP, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J Clin Oncol 2007; 25 (abstract 5096).
22. Beck J, Bajetta E, Escudier B, Negrier S, Keilholz U, Szczylik C, et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl 2007; 5:300 (abstract 4506).
23. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25 (abstract 5025).
24. Amato RJ, Harris P, Dalton M, Khan M, Alter R, Zhai Q, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007; 25 (abstract 5026).
25. Drabkin HA, Figlin RA, Stadler WM, Hutson TE, Hajdenberg J, Chu L, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J Clin Oncol 2007; 25 (abstract 5041).
26. Hutson TE, Davis ID, Machiels JP, de Souza PL, Hong BF, Rottey S, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007; 25 (abstract 5031).
27. Sridhar SS, Hotte SJ, Mackenzie MJ, Kollmannsberger C, Haider MA, Pond GR, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. J Clin Oncol 2007; 25 (abstract 5093).
28. Van Herpen C, Drevs J, van Cruijsen H,Voest EE, Punt CJ, Robertson J, et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two phase I studies. J Clin Oncol 2007; 25 (abstract 3560).
29. Sablin MP, Bouaita L, Balleyguier C, Gautier J, Celier C, Balcaceres JL, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 2007; 25 (abstract 5038).
30. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007; 25 (abstract 5106).
31. Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23 (abstract 4509).
32. Rini BI, Wilding GT, Hudes G, Stadler WM, Kim S, Tarazi JC, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 2007; 25 (abstract 5032).
33. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
34. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007; 25 (abstract 5033).
35. Parasuraman S, Hudes G, Levy D, Strahs A, Moore L, DeMarinis R, et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR. J Clin Oncol 2007; 25 (abstract 5049).
36. Temsirolimus and sorafenib as second-line therapy in patients with advanced RCC who failed first-line sunitinib. Protocol ID: 3066K1-404, NCT00474786.
37. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007; 25 (abstract 5107).
38. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an α5ß1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J Clin Oncol 2007; 25 (abstract 5094).
39. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
40. Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol. 2007; 25 (abstract 3).
41. Patel PH, Kondagunta GV, Redman BG, Hudes GR, Kim ST, Chen I, et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007; 25 (abstract 5097).
42. Kondagunta GV, Hudes GR, Figlin R, Wilding G, Hariharan S, Kempin SN, et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): results of a dose-finding study. J Clin Oncol 2007; 25 (abstract 5101).
43. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25:3296-3301.
44. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25:3288-3295.
45. Bracarda S, Porta C, Boni C, Santoro A, Artioli F, di Bartolomeo C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681. J Clin Oncol 2007; 25 (abstract 5100).
46. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25 (abstract 5104).
47. Speca JC, Mears AL, Creel PA, Yenser SE, Bendell JC, Morse MA, et al. Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol 2007; 25 (abstract 5039).
48. Shinohara N, Harabayashi T, Sazawa A, Nonomura K, Watarai Y, Kumagai A, et al. Combination therapy of meloxicam, a selective COX-2 inhibitor, and interferon alfa in metastatic renal cell carcinoma: a phase II study on efficacy and toxicity. J Clin Oncol 2007; 25 (abstract 5105).
49. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163-2172.
50. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376-2381.
51. Herrmann E, Brinkmann OA, Bode ME, Bierer S, Kopke T, Bogemann M, et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil. Eur Urol 2006; 13:13.
52. Stadler WM, Figlin RA, Ernstoff MS, Curti B, Pendergrass K, Srinivas S, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007; 25 (abstract 5036).
53. Plantade A, Choueiri T, Escudier B, Rini B, Negrier S, Ravaud A, et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 2007; 25 (abstract 5037).
54. Staehler M, Haseke N, Schöppler G, Stadler T, Stief CG. Sorafenib (Nexavar) beim metastasierten sarkomatoiden Nierenzellkarzinom nach Versagen einer vorangegangenen Chemotherapie mit Doxorubicin und Gemcitabine [Application of sorafenib (Nexavar) in metastatic sarcomatoid renal cancer after failure to doxirubicin/gemcitabine-based chemotherapy]. J Urol Urogyn 2007; 14 (abstract 143).
55. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81-83.
56. Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 2007; 25 (abstract 5027).
57. Feldman DR, Kondagunta GV, Ronnen EA, Fischer P, Chang R, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007; 25 (abstract 5099).
58. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard JJ, et al. Guidelines on renal cell carcinoma. In: European Association of Urology: pocket guidelines, Edition 2007. Arnhem: European Association of Urology; 2007. pp. 36-47.